Drug Type Bispecific antibody |
Synonyms ANT 638, ANT638 |
Target |
Mechanism FZD4 agonists(frizzled class receptor 4 agonists), LRP6 inhibitors(LDL receptor related protein 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization AntlerA Therapeutics, Inc.Startup |
Active Organization AntlerA Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma | Preclinical | CA | AntlerA Therapeutics, Inc.Startup | 14 Jun 2024 |
Retinal Diseases | Preclinical | CA | AntlerA Therapeutics, Inc.Startup | 14 Jun 2024 |